

Highlights of This Issue 219

THERAPEUTIC DISCOVERY

- 221 | **Antisense Inhibition of Survivin Expression as a Cancer Therapeutic**
Rosa A. Carrasco, Nancy B. Stamm, Eric Marcusson, George Sandusky, Philip Iversen, and Bharvin K.R. Patel
- 233 | **Spliceosome-Mediated RNA *Trans*-Splicing Facilitates Targeted Delivery of Suicide Genes to Cancer Cells**
Christina Gruber, Iris K. Gratz, Eva M. Muraier, Elisabeth Mayr, Ulrich Koller, Leena Bruckner-Tuderman, Guerrino Meneguzzi, Helmut Hintner, and Johann W. Bauer
- 242 | **A Robust High-Content Imaging Approach for Probing the Mechanism of Action and Phenotypic Outcomes of Cell-Cycle Modulators**
Jeffrey J. Sutherland, Jonathan Low, Wayne Blosser, Michele Dowless, Thomas A. Engler, and Louis F. Stancato
- 255 | **Anticancer Activity of a Combination of Cisplatin and Fisetin in Embryonal Carcinoma Cells and Xenograft Tumors**
Rakshamani Tripathi, Tanmoy Samadder, Sarika Gupta, Avadhesh Surolia, and Chandrima Shaha
- 269 | **p53R2 Inhibits the Proliferation of Human Cancer Cells in Association with Cell-Cycle Arrest**
Keqiang Zhang, Jun Wu, Xiwei Wu, Xiaochen Wang, Yan Wang, Ning Zhou, Mei-ling Kuo, Xiyong Liu, Bingsen Zhou, Lufen Chang, David Ann, and Yun Yen

PRECLINICAL DEVELOPMENT

- 279 | **Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of *Nf1*-Deficient Astrocytes**
Sutapa Banerjee, Scott M. Gianino, Feng Gao, Uwe Christians, and David H. Gutmann
- 292 | **Low-Dose Fractionated Radiation Potentiates the Effects of Cisplatin Independent of the Hyper-Radiation Sensitivity in Human Lung Cancer Cells**
Seema Gupta, Tulay Koru-Sengul, Susanne M. Arnold, Gayathri R. Devi, Mohammed Mohiuddin, and Mansoor M. Ahmed
- 303 | **Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells**
Rouba Hage-Sleiman, Stéphanie Herveau, Eva-Laure Matera, Jean-Fabien Laurier, and Charles Dumontet
- 313 | **Chromatin Structure Predicts Epigenetic Therapy Responsiveness in Sarcoma**
Joslyn Mills, Todd Hricik, Sara Siddiqi, and Igor Matushansky
- 325 | **Ovarian Cancer Stem Cell-Like Side Populations Are Enriched Following Chemotherapy and Overexpress *EZH2***
Siân Rizzo, Jenny M. Hersey, Paul Mellor, Wei Dai, Alessandra Santos-Silva, Daniel Liber, Louisa Luk, Ian Titley, Craig P. Carden, Garry Box, David L. Hudson, Stanley B. Kaye, and Robert Brown
- 336 | **Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy**
Noriaki Sunaga, David S. Shames, Luc Girard, Michael Peyton, Jill E. Larsen, Hisao Imai, Junichi Soh, Mitsuo Sato, Noriko Yanagitani, Kyoichi Kaira, Yang Xie, Adi F. Gazdar, Masatomo Mori, and John D. Minna

**Transcription Factor Stat5
Knockdown Enhances Androgen
Receptor Degradation and Delays
Castration-Resistant Prostate Cancer
Progression *In vivo***


Christian Thomas, Amina Zoubeidi,
Hidetoshi Kuruma, Ladan Fazli,
Francois Lamoureux, Eliana Beraldi,
Brett P. Monia, A. Robert MacLeod,
Joachim W. Thüroff, and Martin E. Gleave

**Preclinical Pharmacology, Antitumor
Activity, and Development of
Pharmacodynamic Markers for the
Novel, Potent AKT Inhibitor
CCT128930**

Timothy A. Yap, Mike I. Walton, Lisa-Jane K.
Hunter, Melanie Valenti,
Alexis de Haven Brandon, Paul D. Eve,
Ruth Ruddle, Simon P. Heaton, Alan Henley,
Lisa Pickard, Gowri Vijayaraghavan,
John J. Caldwell, Neil T. Thompson,
Wynne Aherne, Florence I. Raynaud,
Suzanne A. Eccles, Paul Workman,
Ian Collins, and Michelle D. Garrett

ABOUT THE COVER

Multivariate analysis and high-content imaging allow the detailed investigation of treatment effects at the cellular level, yet the reproducibility of such assessments has not been thoroughly investigated. A model calibrated at each experiment accounts for variation in experimental conditions and allows for the reproducible assessment of phenotype induced by cell cycle modulators. An extensive survey of cell cycle inhibitors highlights the prevalence of phenotypic variability in response to agents within a mechanistic class and the occurrence of concentration-dependent changes in phenotype. For details, see the article by Sutherland and colleagues on page 242.



Molecular Cancer Therapeutics

10 (2)

Mol Cancer Ther 2011;10:219-371.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/10/2>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://mct.aacrjournals.org/content/10/2>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.